109 results
424B3
ATXI
Avenue Therapeutics Inc
10 May 24
Prospectus supplement
4:53pm
information to support the position that the benefits of their product outweigh the risks for the management of acute pain severe enough to require an opioid … ) and certify under penalty of perjury that such holder is not a United States person as defined under the Code and is eligible for treaty benefits
424B5
ATXI
Avenue Therapeutics Inc
10 May 24
Prospectus supplement for primary offering
4:52pm
the position that the benefits of their product outweigh the risks for the management of acute pain severe enough to require an opioid analgesic
8-K
EX-4.1
ATXI
Avenue Therapeutics Inc
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
be entitled to the benefits of the provisions of this Section 3(e) regardless of (i) whether the Company has sufficient authorized shares of Common Stock
8-K
EX-4.2
ATXI
Avenue Therapeutics Inc
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
be entitled to the benefits of the provisions of this Section 3(e) regardless of (i) whether the Company has sufficient authorized shares of Common Stock
8-K
EX-4.3
1oby92kzj2
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
8-K
EX-10.1
ex5jelmh3idjv4
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
424B3
f79psk
2 Feb 24
Prospectus supplement
12:00am
8-K
EX-4.1
kqnz1a5
8 Jan 24
Entry into a Material Definitive Agreement
5:28pm
8-K
EX-4.2
5z6v3
8 Jan 24
Entry into a Material Definitive Agreement
5:28pm
8-K
EX-10.2
naf0 f096kflpohy435
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-10.1
mj82yvn7op mf
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-4.2
wkmy2
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-4.1
6tf6iqjo2 uq
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
424B4
zns93
2 Nov 23
Prospectus supplement with pricing info
9:00am